Ultragenyx Pharmaceutical Inc (Ultragenyx) develops novel medicines for rare and ultra-rare genetic diseases. It has three marketed products, Mepsevii (vestronidase alfa) for the treatment of Mucopolysaccharidosis (Sly syndrome); Dojolvi (triheptanoin), a highly purified, synthetic, 7-carbon fatty acid triglyceride for long-chain fatty acid oxidation disorders (LC-FAOD) and Crysvita (burosumab), a fully human monoclonal antibody for the treatment of X-linked hypophosphatemia (XLH). Its pipeline includes DTX401 for the treatment of glycogen storage disease type Ia, or GSDIa; UX701 for Wilson disease; UX053 for glycogen storage disease type III; and GTX-102 for Angelman syndrome in partnership with GeneTx. It works in partnership with various academic institutes and biotechnology companies to advance its product candidates. Ultragenyx is headquartered in Novato, California, the US.
Headquarters
United States of America
Address
60 Leveroni Ct, Novato, California, 94949-5746
Website
www.ultragenyx.com
Telephone
1 415 4838800
No of Employees
1,119
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
RARE (NASD)
Revenue (2020)
$351.4M
29.7%
(2020 vs 2019)
EPS
XXX
Net Income (2020)
XXX
-143.4%
(2020 vs 2019)
Market Cap*
$3.7B
Net Profit Margin (2020)
XXX
-87.7%
(2020 vs 2019)
* As of and is in US$
Access premium data and analytics for Ultragenyx Pharmaceutical Inc
Products and Services
| Products | Brands |
|---|---|
| Crysvita - X-linked hypophosphatemia and Tumor-Induced Osteomalacia | Ultragenyx |
| Mepsevii - Mucopolysaccharidosis VII | Crysvita |
| Dojolvi - Long Chain Fatty-Acid Oxidation Disorders | Mepsevii |
| XXX | XXX |
| XXX | XXX |
| XXX | XXX |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2022 | Acquisitions/Mergers/Takeovers | In July, the company acquired GeneTx BioTherapeutics for US$75 million. |
| 2022 | Stake Sale | In July, the company announced the sale of 30% royalty interest from Kyowa Kirin Co., Ltd on the future sales of Crysvita (burosumab) in the U.S. and Canada to OMERS. |
| 2022 | Acquisitions/Mergers/Takeovers | In July, the company acquired marketing rights of Mepsevii in Japan from Amicus Therapeutics. |
Competitor Comparison
| Key Parameters | Ultragenyx Pharmaceutical Inc | Pfizer Inc | Sanofi | Amgen Inc | Acer Therapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | France | United States of America | United States of America |
| City | Novato | New York | Paris | Thousand Oaks | Newton |
| State/Province | California | New York | - | California | Massachusetts |
| No. of Employees | 1,119 | 79,000 | 95,442 | 24,200 | 35 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Daniel G. Welch | Chairman | Executive Board | 2015 | 64 |
| Emil D. Kakkis, M.D., Ph.D. | Director; President; Chief Executive Officer | Executive Board | 2010 | 61 |
| Mardi C. Dier | Chief Financial Officer; Executive Vice President | Senior Management | 2020 | 58 |
| Karah Parschauer | Executive Vice President; General Counsel; Chief Legal Officer | Senior Management | 2016 | 44 |
| Camille L. Bedrosian, M.D. | Chief Medical Officer; Executive Vice President | Senior Management | 2018 | 69 |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer